2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6034 Relapse burden and anatomic site predict survival after allogeneic hematopoietic cell transplantation for AML and MDS/AML

Phuong T Vo, MD, Sarah Doherty2, Othus Megan, PhD3, Hosea Nacanaynay4, Margery Gang, MD, MA5, Brenda M Sandmaier, MD6, Chris Davis7, Ryan Basom8, Roland Bruno Walter, MD, PhD, MS9
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States

Introduction: Relapse is the most common cause of treatment failure following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and related myeloid neoplasms· However, relapse patterns and their prognostic implications are not well defined·

Methods: We retrospectively evaluated 440 adults with AML or MDS/AML, as defined by the 2022 International Consensus Classification, who received a first allograft at our institution between 2006 and 2024 while in first or second morphologic remission and subsequently relapsed. Relapse was categorized using a hierarchical schema into four mutually exclusive phenotypes: measurable residual disease (MRD)-only relapse, defined as abnormal bone marrow flow cytometry or cytogenetic/FISH evidence of disease without morphologic marrow relapse, circulating blasts, or extramedullary (EM) leukemia; blood relapse, defined as any evidence of circulating blasts; morphologic marrow relapse; or EM relapse. Overall survival (OS) was calculated from the date of relapse. Cox proportional hazards models assessed associations of relapse phenotype with time to relapse and OS. Multivariable models adjusted for age at transplant, sex, ECOG performance status, 2022 ELN cytogenetic risk, remission status at HCT, pre-HCT MRD status by flow cytometry, cytogenetic status at HCT, HCT-CI, donor type, history of EM/CNS disease before HCT, transplant era defined as before and after 2014, conditioning intensity, and, for OS, relapse timing.

Results: Among 440 relapsed patients, median age at HCT was 57.6 years; 204 (46%) were female, 277 (63%) had de novo AML, 97 (22%) secondary AML, and 65 (15%) MDS/AML. Most patients were transplanted in first remission (n=344, 78%), while 96 (22%) were in second remission. Pre-HCT MRD was present in 163 (37%), and adverse-risk cytogenetics at diagnosis were present in 172 (39%). Donors included 10/10 HLA-matched unrelated donors (n=224, 51%), matched related donors (n=108, 25%), mismatched unrelated donors (n=46,10%), cord blood (n=41, 9%), and haploidentical donors (n=21, 5%). Peripheral blood was the most common graft source (361, 82%); conditioning intensity was myeloablative in 245 (56%), reduced intensity in 67 (15%), and nonmyeloablative in 128 (29%).

Relapse phenotypes were MRD relapse in 129 patients (29%), blood relapse in 126 (29%), morphologic marrow relapse in 143 (32%), and EM relapse in 42 (10%). Clinical and transplant features varied across phenotypes: EM relapse patients more often had prior EM/CNS disease and relapsed later after HCT; MRD relapse patients had the highest proportion of pre-HCT MRD positivity; and morphologic marrow relapse patients more often received lower-intensity conditioning. Median time from HCT to relapse was shortest for MRD relapse (2.7 months; range, 0.6–77.6), followed by morphologic marrow relapse (4.3 months; range, 0.5–97.2), blood relapse (5.4 months; range, 0.4–108.0), and EM relapse (18.5 months; range, 0.5–101.5). Relapse within 1 year occurred in 89% (95% CI, 83%–93%), 82% (95% CI, 74%–88%), 75% (95% CI, 67%–81%), and 29% (95% CI, 17%–44%) of patients with MRD, blood, morphologic marrow, and EM relapse, respectively.

After multivariable adjustments, compared with MRD relapse, blood relapse, morphologic marrow relapse, and EM relapse occurred significantly later after HCT, with hazard ratios (HRs) of 0.55 (95% CI, 0.41–0.72), 0.54 (0.41–0.71), and 0.23 (0.16–0.34), respectively (all p<0.001). Post-relapse OS also differed by relapse phenotype. Compared with MRD relapse, all other relapse phenotypes were independently associated with inferior OS: blood relapse HR=2.44 (1.83–3.25), morphologic marrow relapse HR=1.78 (1.35–2.35), and EM relapse HR=2.21 (1.40–3.49; all p<0.001). Relapse more than 1 year after HCT was independently associated with improved OS (HR=0.54 [0.40–0.73]; p<0.001).

Conclusions: Relapse phenotype after allogeneic HCT is clinically informative and independently associated with both relapse timing and post-relapse survival. MRD relapse identified a distinct group with the shortest time to relapse but comparatively better post-relapse survival, whereas blood and morphologic marrow relapse conferred poorer outcomes; EM relapse represented a later but still high-risk pattern. Incorporating relapse burden and anatomic site into post-HCT relapse classification may refine risk assessment and support development of relapse phenotype-specific surveillance and intervention strategies.

 

Phuong T Vo, MD: Medexus Pharmaceuticals, Inc. - Research Funding